Clinical Guidelines

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

Share

Recent advancements in extensive-stage small cell lung cancer (ES-SCLC) treatment were highlighted at JADPRO Live by nurse practitioners Stephanie McDonald and Elizabeth Castronovo from Dana-Farber Cancer Institute. They addressed current therapies, including immunotherapy agents like durvalumab and atezolizumab, which significantly extend survival rates. The presenters also detailed management strategies for treatment-related adverse events, emphasizing the importance of supportive care in patient outcomes, particularly for this aggressive disease with historically low survival rates.

Original Source(s)

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

  • by Stephanie McDonald, MSN, FNP-BC, AOCNP, Elizabeth Castronovo, MSN, AGNP-BC

  • February 27, 2026

  • 8 min

Related Content

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min
Case Study: ICU-Based Chemotherapy for High-Risk Cardiac DLBCL Patient

A 34-year-old woman with newly diagnosed mediastinal diffuse large B-cell lymphoma developed alarming cardiac symptoms during her initial hospitalization.

  • by

  • January 31, 2026

  • 4 min
Uncovering and Addressing Implicit Bias in Oncology

  • April 24, 2023

  • 12 min